[en] The objective of the present study was to analyze the pattern of oral contraceptive (OC) use in teenagers and to examine the relationship between OC use and other cardiovascular risk factors. The study was conducted in 24 Belgian secondary schools. Most students (1526 adolecents aged 12-17 years) agreed to participate (participation rate: 83.6%). Smoking, physical activity habits, menarche, and OC use were assessed by a self-administered questionnaire. Total cholesterol level, blood pressure and anthropometric measurements were also measured. Fourteen per cent of mature girls (14%, n=92) were OC users. Two-thirds of them (66.3%, n=61) were taking OC which contained either gestodene or desogestrel. Blood pressure and BMI were similar for OC users and non-users. Total cholesterol level was significantly higher in OC users than in non-users (191 mg/dL versus 172 mg/dL). Logistic regression model confirmed the significant influence of OC use on total cholesterol level (OR=3.08). OC users were also often smokers (39% versus 20% for non-users). In conclusion, the present study has found significant relationship between OC use and cardiovascular risk factors i.e., high total cholesterol and smoking. The first implication is a need for further research on lipoprotein profile in young OC users. Secondly, the combined use of OC and smoking in teenagers calls for preventive actions.
Disciplines :
Public health, health care sciences & services Urology & nephrology
Author, co-author :
Paulus, Dominique; Interuniversity Association for Cardiovascular Disease Prevention, Clos Chapelle-aux-Champs 30/53, Brussels, Belgium
Saint-Remy, Annie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
JeanJean, Michel; Interuniversity Association for Cardiovascular Disease Prevention, Clos Chapelle-aux-Champs 30/53, Brussels, Belgium
Language :
English
Title :
Oral contraception and cardiovascular risk factors during adolescence
Van Hoff M., Hirasing R., Kaptein M., Koppenaal C., Voorhorst F., Schoemaker J. (1998) The use of oral contraceptives by adolescents for contraception, menstrual cycle problems or acne. Acta Obstet Gynecol Scand 77:898-904.
Archer D., Maheux R., DelConte A. (1999) Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol. Am J Obstet Gynecol 181:S39-S44.
Beral V., Hermon C., Kay C., Hannaford P., Darby S., Reeves G. (1999) Mortality associated with oral contraceptive use; 25-year follow-up of cohort of 46,000 women from Royal College of General Practitioners' oral contraception study. Bmj 318:96-100.
Dunn N., Thorogood M., Faragher B. (1999) Oral contraceptives and myocardial infarction; results of the MICA case-control study. Bmj 318:1579-1584.
Farley T., Collins J., Schlesselman J. (1998) Hormonal contraception and risk of cardiovascular disease. Contraception 57:211-230.
Lachnit-Fixson U. (1996) The role of triphasic levonorgestrel in oral contraception; a review of metabolic and hemostatic effects. Gynecol Endocrinol 10:207-218.
Farmer R., Lawrenson R., Thompson C., Kennedy J., Hambleton I. (1997) Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349:83-88.
Jick H., Jick S., Gurewich V., Myers M., Vasilakis C. (1995) Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346:1589-1593.
Poulter N., Chang C., Farley T., Marmot M., Meirik O. (1999) Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. Lancet 354:301-302.
Spitzer W., Lewis M., Heinemann L., Thorogood M., MacRae K. (1996) Third generation oral contraceptives and risk of venous thromboembolic disorders; an international case-control study. Bmj 312:83-88.
.
.
.
.
Lapinleimu H., Viikari J., Jokinen E. (1994) Cholesterol measurements by Reflotron dry chemistry in infants, children and adults. Scand J Clin Lab Invest 54:61-65.
.
.
.
Cerel-Suhl S., Yeager B. (1999) Update on oral contraceptive pills. Am Fam Physician 60:2073-2084.
Gold M. (1999) Prescribing and managing oral contraceptive pills and emergency contraception for adolescents. Pediatr Clin North Am 46:695-718.
Flint P., Lapane K., Barbour M., Derby C., Carleton R., Hume A. (1995) Cardiovascular risk profiles of oral contraceptive users and non-users; a population-based study. Prev Med 24:586-590.
.
Akerlund M., Almstrom E., Hogstedt S., Nabrink M. (1994) Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Acta Obstet Gynecol Scand 73:136-143.
Laurendeau L. (1996) Desogestrel contraceptives; the perfect pill for lipids?. Can Fam Physician 42:62-71.
Fotherby K. (1995) Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyl estradiol and 150 micrograms desogestrel. Contraception 51:3-12.
Lobo R., Skinner J., Lippman J., Cirillo S. (1996) Plasma lipids and desogestrel and ethinyl estradiol; a meta-analysis. Fertil Steril 65:1100-1109.
Fuchs N., Dusterberg B., Weber-Diehl F., Muhe B. (1995) The effect on blood pressure of a monophasic oral contraceptive containing ethinylestradiol and gestodene. Contraception 51:335-339.
Risser W., Gefter L., Barratt M., Risser J. (1999) Weight change in adolescents who used hormonal contraception. J Adol Health 24:433-436.
Raitakari O., Porkka K., Rasanen L., Viikari J. (1994) Relations of lifestyle with lipids, blood pressure and insulin in adolescents and young adults. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 111:237-246.
.
Kosunen E., Rimpela A., Kaprio J., Berg M. (1997) Oral contraception and smoking. Eur J Public Health 7:29-33.
